Objective: Neprilysin (NEP), a zinc metalloendopeptidase, has a role in blood pressure control and lipid metabolism. The present study tested the hypothesis that NEP is associated with insulin resistance and features of the metabolic syndrome (MetS) in a study of 318 healthy human subjects and in murine obesity, and investigated NEP production by adipocytes in-vitro. Methods and results: In 318 white European males, plasma NEP was elevated in the MetS and increased progressively with increasing MetS components. Plasma NEP activity correlated with insulin, homoeostasis model assessment and body mass index (BMI) in all subjects (Po0.01). Quantitative reverse transcriptase PCR (RT-PCR) and western blotting showed that in human preadipocytes NEP expression is upregulated 25-to 30-fold during differentiation into adipocytes. Microarray analysis of mRNA from differentiated human adipocytes confirmed high-NEP expression comparable with adiponectin and plasminogen activator inhibitor-1. In a murine model of diet-induced insulin resistance, plasma NEP levels were significantly higher in high-fat diet (HFD)-fed compared with normal chow diet (NCD)-fed animals (1642±529 and 820±487 pg ml À1 , respectively; Po0.01). Tissue NEP was increased in mesenteric fat in HFD compared with NCD-fed mice (Po0.05). NEP knockout mice did not display any changes in insulin resistance, glucose tolerance, or body and epididymal fat pad weight compared with wild-type mice. Conclusion: In humans, NEP activity correlated with BMI and measures of insulin resistance with increasing levels in subjects with multiple cardiovascular risk factors. NEP protein production in human adipocytes increased during cell differentiation and plasma and adipose tissue levels of NEP were increased in obese insulin-resistant mice. Our results indicate that NEP associates with cardiometabolic risk in the presence of insulin resistance and increases with obesity.
Introduction
Neprilysin (NEP, neutral endopeptidase, EC3 4.24.11) is a mammalian integral membrane zinc metalloendopeptidase widely expressed on the surface of a variety of cells, including endothelial, epithelial and smooth muscle cells, cardiac myocytes and fibroblasts. 1, 2 NEP cleaves peptides at the N-terminal side of hydrophobic amino-acid residues and is responsible for the degradation and inactivation of a number of bioactive peptides, including endothelins, angiotensins I and II, bradykinin, atrial natriuretic peptide, enkephalins, substance P and chemotactic peptides. The vasopeptidase inhibitor omapatrilat simultaneously inhibits angiotensin-converting enzyme (ACE) and NEP, [3] [4] [5] and in normotensive volunteers and hypertensive subjects, omapatrilat produced greater decreases in systolic and diastolic pulse pressure levels than ACE inhibition alone, 6, 7 indicating that NEP might have a role in blood pressure regulation.
NEP is also produced by adipocytes, 8 raising the possibility that it might have a role as an adipokine, regulating aspects of adipocyte function. In support of this, inhibition of NEP in obese insulin-resistant Zucker rats improved whole-body insulin-mediated glucose disposal, and dual ACE/NEP inhibition induced profound insulin sensitization and increased myocardial glucose uptake. [9] [10] [11] These latter studies suggest that NEP directly contributes to the development of insulin resistance.
A soluble form of NEP is present in plasma and levels have been measured in several studies. [12] [13] [14] [15] Recently, we determined the heritability of plasma NEP and its contribution to variance in systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels in the Leeds Family Study. In addition to associations of NEP with SBP and DBP, we observed correlations of NEP with body mass index (BMI), cholesterol and triglycerides. 16 The results of these studies indicate that NEP associates with the regulation of insulin resistance, blood pressure and lipid metabolism. To investigate this association further, we studied (i) the clinical relationship between NEP activity, obesity, insulin resistance and components of the metabolic syndrome (MetS) in 318 healthy individuals characterized for insulin resistance using the homoeostasis model assessment (HOMA) and the presence of the MetS according to the definition of International Diabetes Federation (IDF), (ii) the expression of NEP in human Simpson-Golabi-Behmel syndrome (SGBS) adipocytes during differentiation in vitro, (iii) the effect of diet-induced insulin resistance and obesity on plasma and tissue NEP levels in a murine model and (iv) metabolic characteristics of NEP knockout (NEPKO) mice.
Materials and methods
Clinical study of healthy volunteers Subjects. The study population comprised of 318 clinically healthy white males of European origin, characterized for the presence of the MetS and in whom stored plasma was available for analysis of NEP. Participant recruitment has been published previously. 17, 18 In brief, all subjects were free from clinical cardiovascular disease or previously diagnosed diabetes. Fasting venous blood samples were taken for analysis of lipid subfractions, glucose and insulin and haemostatic factors as previously described. SBP and DBP levels, mean of three readings, were measured to the nearest 2 mm Hg, with subjects in a sitting position. All subjects gave informed consent according to a protocol approved by the Leeds Teaching Hospitals Trust Research Ethics Committee, in accordance with institutional guidelines and the Declaration of Helsinki.
Biochemical analyses. Analysis of fasting lipids, glucose, insulin and HOMA, tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) was carried out as previously described. 17, 18 NEP was assayed according to an original protocol 19 modified in our laboratory using the fluorogenic substrate succinoyl-Ala-Ala-Phe-7-amido-4methylcoumarin (200 mM) in a coupled assay with leucine aminopeptidase (50 mg ml À1 ) in 50 mM Hepes/NaOH, 200 mM NaCl, 10 mM ZnCl 2 , 1% dimethyl sulfoxide (DMSO), pH 6.8 at room temperature in the dark. Fluorescence was measured using a Biotek Synergy HT plate reader (Biotek, Polton, UK) (l excitation ¼ 380 nm and l emission ¼ 460 nm). Enzyme activity (relative fluorescence units) in the plasma sample was converted to a concentration of enzyme by reference to a standard curve of recombinant human NEP (R&D Systems, Abingdon, UK) assayed under the same conditions. The lower limit of detection for this assay was 0.0027 nmol NEP per litre. The inter-and intra-assay coefficients of variation were 6.9 and 2.5%, respectively.
Definition of metabolic syndrome. Presence of the MetS was defined according to the IDF criteria 20 as waist circumference X94 cm (MetS IDF waist) plus any two of the following: triglycerides X1.7 mmol l À1 (MetS IDF TG), high-density lipoprotein (HDL) cholesterol o1.03 mmol l À1 (MetS IDF HDL), treatment of previously diagnosed hypertension or SBPX130 mm Hg or DBPX85 mm Hg (MetS IDF HT), fasting glucose X5.6 mmol l À1 or previously diagnosed type 2 diabetes (MetS IDF DM/IFG).
Cell and murine studies Neprilysin expression in differentiating human Simpson-Golabi-Behmel syndrome cells Cell culture: Human SGBS pre-adipocytes, originally derived from the stromal fraction of subcutaneous adipose tissue of an infant with SGBS, were cultured as described previously. 21, 22 Briefly, SGBS pre-adipocytes were maintained in DMEM/Ham's F12 (1:1) culture medium containing 10% foetal bovine serum, 8 mg ml À1 biotin, 4 mg ml À1 pantothenate, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. To obtain basal serum-free medium (OF medium), supplementation of foetal bovine serum was omitted. Cells were seeded into the appropriate sterile plastic at 4000 cells per cm 2 , incubated at 37 1C in a humidified atmosphere containing 5% CO 2 /95% O 2 and grown to confluence. After reaching confluence (day 0), adipogenic differentiation was induced by incubation with OF medium supplemented with 10 mg ml À1 apo-transferrin, 20 nM recombinant human insulin, 0.1 mM hydrocortisone and 200 pM triiodo-L-thyronine. For the first 4 days, this adipogenic culture medium was additionally supplemented with 25 nM dexamethasone, 0.5 mM IBMX and 2 mM rosiglitazone. Cell medium was changed on days 4 and 9. Cells were used between passages 31-36.
Microarray analysis: Human Genome U133 Plus 2.0 array (Affymetrix UK Ltd, High Wycombe, UK) was used for mRNA expression profiling. Total RNA was extracted from 14-day differentiated SGBS cells using a TRIzol Plus RNA purification kit (Invitrogen, Paisley, UK) according to the manufacturers instructions. First and second strand cDNA were synthesized from 3 mg of total RNA, in vitro transcribed, and fragmented using the recommended Affymetrix reagents and kits. Samples were hybridized to the HG-U133 Pus 2.0 (Affymetrix UK Ltd), array, processed by the fluidics station and scanned using an Affymetrix GeneChip Scanner 3000 (Affymetrix UK Ltd). The captured images were analysed using Affymetrix GeneChip Operating Software (GCOS) v 1.4 (Affymetrix UK Ltd).
Total RNA isolation and real-time RT-PCR: Total RNA was isolated by TRIzol extraction as described above. Samples Neprilysin and the metabolic syndrome KF Standeven et al were taken every two days, starting from day 0 (undifferentiated) to 14 days differentiation. Reverse transcription was carried out using a TaqMan Reverse Transcription Kit (Applied Biosystems, Warrington, UK) and real-time quantitative PCR was performed with an ABI 7900HT Sequence Detection System (Applied Biosystems) using the TaqMan Universal PCR Master Mix protocol. Primers and TaqMan probe for the human NEP gene were obtained from Applied Biosystems as a TaqMan Gene Expression Assay (Assay I.D. Hs00153519_m1). Forward and reverse primers for human GAPDH (5 0 -GCTCCTCCTGTTCGACAGTCA-3 0 and 5 0 -ACC TTCCCCATGGTGTCTGA-3 0 , respectively) were obtained from Invitrogen. The TaqMan probe for human GAPDH (VIC-5 0 -TTCTTTTGCGTCGCCAGCCGAG-3 0 -TAMRA) was custom synthesized by Applied Biosystems. All reactions were carried out in triplicate. PCR cycling conditions were as follows: 95 1C for 10 min followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. NEP mRNA levels were normalized to the values of the endogenous control GAPDH and the results expressed as fold changes relative to undifferentiated cells using the 2 ÀDDCT method. 22 Western blotting: During differentiation, Triton X-100 solubilized protein was isolated from cells every two 2 days, from day 0 to day 14. Cells were harvested in 50 mM Tris, pH 7.4, containing 1% Triton X-100, Protease Inhibitor Cocktail I and Phosphatase Inhibitor Cocktail 2 (all from: Sigma-Aldrich, Poole, UK) and placed on ice for 30 min. Following centrifugation (10 min, 13 000 g), protein content in the supernatant was determined using a BCA protein Assay Kit (Thermo Scientific, Cramlington, UK). Samples containing 5 mg of protein were separated on a NuPAGe 4-12% Bis-Tris Gel (Invitrogen) and transferred to a PVDF membrane. NEP was detected using an anti-human NEP mouse monoclonal antibody (Novocastra, Newcastle, UK), a rabbit anti-mouse horseradish peroxidise conjugate (Dako UK Ltd, Ely, UK) and enhanced chemiluminescent reagent (Thermo-Scientific). Fold changes in NEP expression relative to undifferentiated cells were calculated from the signal intensities derived using Kodak 1D software (version 3.6) (Kodak, Munich, Germany).
Neprilysin expression in a murine model of obesity
Murine husbandry. Male C57BL/6J mice (Charles River Laboratories, Margate, UK) were bred and housed in a temperature-controlled facility with a 12 h light/dark cycle. Mice (n ¼ 8) were fed a high-fat diet (HFD) (5286 kcal kg À1 , 60% kcal from fat Bio-Serv (Frenchtown, NJ, USA) from weaning onwards for 15 weeks. Control animals (n ¼ 8) received a normal chow diet (NCD). All mice had free access to drinking water and food. Body weight was recorded weekly. At 14 weeks, HFD animals were metabolically phenotyped, including an intraperitoneal glucose tolerance test using a dose of 1 mg glucose per gram body weight and an insulin tolerance test by the intraperitoneal injection of 0.5-unit human recombinant insulin per kg body weight. Tail vein blood was used for glucose quantification using a Glucometer (Roche Accucheck, Burgess Hill, UK) during glucose tolerance test and insulin tolerance test. After 15 weeks, animals were sacrificed; mesenteric, epididymal and perirenal adipose tissue, liver and kidney were harvested; and weights of epididymal fat pads were recorded. Tissues were snap frozen in liquid nitrogen and stored at À80 1C. All procedures were performed in accordance with the UK Guidance on the Operation of the Animals (Scientific Procedures) Act (1986).
Murine plasma and tissue levels of neprilysin. After 7 and 15 weeks of HFD, mice were bled from the lateral saphenous vein. Blood was collected in Microvette lithium heparin 300 tubes (Sarstedt, Leicester, UK) and centrifuged for 10 min at 11 336 g. Plasma was stored at À80 1C. NEP protein levels were measured using the NEP mouse DuoSet kit (R&D Systems, Abingdon, UK) following the manufacturer's instructions. Plasma was diluted 2.66-fold with phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , pH7.4) containing 20% foetal calf serum.
To measure NEP protein levels in liver, kidney, epididymal, mesenteric and perirenal fat, 100 mg tissue per organ was homogenized in 50 mM Tris, pH 7.4, 100 mM NaCl and 0.5% Triton-X100 (Sigma-Aldrich). Tissues were disrupted by rapid agitation using a Qiagen TissueLyser (Qiagen, Crawley, UK) in tubes containing stainless steel cones. The homogenate was incubated on ice for 60 min and centrifuged at 135 000 g for 60 min. The supernatant was diluted 8-fold with phosphate buffered saline containing 20% foetal calf serum. Total protein levels were measured using a BCA protein assay kit (Thermo Scientific) and results were expressed as a ratio of ng NEP per mg total protein. The results are presented as median and 25 and 75th percentiles.
Metabolic characteristics of NEPKO mice in a high-fat feeding model In a separate set of experiments, breeding colonies between NEPKO 23 and C57BL/6J mice were established, and male littermates were subjected twice to glucose and insulin tolerance tests as described above. Equally, their final body and epididymal fat pat weights were recorded. For this study, 10 NEPKO and 8 wild-type littermates were subjected to normal chow, whereas 7 NEPKO and 10 wild-type littermates received the high-fat food described above.
Statistical analyses
In the clinical study, age, cholesterol, low-density lipoprotein cholesterol, SBP, DBP, waist-hip ratio, waist circumference and tPA were normally distributed, and data were presented as mean and 95% confidence intervals. BMI, highdensity lipoprotein cholesterol, triglycerides, insulin, glucose, HOMA, fibrinogen and PAI-1 were log transformed Neprilysin and the metabolic syndrome KF Standeven et al to normalize their distributions for analysis, with data presented as geometric mean and 95% confidence intervals. Individuals with NEP at or below (n ¼ 18) the lower limit of detection were assigned the lower limit of detection value of 0.0027 nmol l À1 . NEP did not have a normal distribution even after log transformation and NEP data was analysed by non-parametric analyses with data presented as a median (25 and 75th percentiles). Categorical data were analysed by w 2 test. Differences in clinical characteristics between subjects with and without the MetS were assessed by independent student t-test for normally distributed variables and by Mann-Whitney U-test for variables that were not normally distributed. Mann-Whitney U tests were employed to determine the association between NEP and components of the metabolic syndrome. The relationship between NEP and the number of features of the MetS was assessed by Kruskal-Wallis test, and bivariate Spearman rank correlation was used to establish the associations between NEP and other cardiovascular risk factors. For linear regression analysis to identify determinants of NEP, those with NEP below the threshold were excluded and NEP was log-transformed to a normal distribution for analysis using forward stepwise selection. Receiver operating characteristic curve analysis was used to determine a cut-point for NEP in relation to MetS IDF ; on the basis of this analysis, NEP was dichotomized according to NEP o0.2028 nmol l À1 or X0.2028 nmol l À1 for further analysis. Logistic regression analysis was utilized to identify factors predicting the presence of MetS and its subcomponents, with data presented as odds ratio and 95% confidence intervals. All analyses were performed using SPSS for Windows version 12.0 (SPSS Inc., Chicago, IL, USA).
Results of the experimental studies are reported as mean±s.e.m., unless otherwise stated. Differences were analysed by t-test or in the case of non-normal distribution by Mann-Whitney U-test. A probability value o0.05 was regarded as significant.
Results
Neprilysin activity is associated with metabolic syndrome, insulin resistance and cardiovascular risk factors in human subjects The clinical and biochemical characteristics of the 318 subjects according to the presence of the MetS are presented in Table 1 . A total of 79 subjects (24.8%) fulfilled the IDF criteria for exhibiting the MetS, 229 subjects (75.2%) did not have the MetS by these criteria. Subjects with the MetS IDF were slightly older with significantly higher BMI, cholesterol, low-density lipoprotein, insulin and HOMA than those without the MetS IDF . The haemostatic factors PAI-1 and tPA were also significantly higher in subjects with the MetS IDF . The prevalence of smoking and family history of cardiovascular disease was similar in the two groups. Plasma NEP concentration was significantly associated with BMI (p for trend o0.0001) increasing from a median (25 and 75th percentiles) of 0.155 (0.048, 0.310) nmol l À1 in those with BMI o25 kg m À2 to 0.358 (0.233, 0.719) nmol l À1 (Po0.001) in those with BMI430 kg m À2 (Figure 1a ). Similarly, there was a stepwise increase in NEP concentration with increasing quartiles of HOMA ( Figure 1b) ; however, only the difference in NEP between quartiles 4 and 1 was significant after adjustment of age, sex and BMI (adjusted NEP levels: 0.199 (0.150, 0.265) nmol l À1 in HOMA quartile 1 versus 0.366 (0.275, 0.488) nmol l À1 in HOMA quartile 4, P ¼ 0.015 after adjustment for multiple comparisons). NEP activity was significantly higher in subjects with the MetS IDF compared with those without (0.38 versus 0.2 nmol l À1 , respectively, Po0.001) the MetS IDF , and increased progressively with the number of MetS IDF components, being B8-fold higher in those with five MetS IDF components compared with those with no MetS IDF (Po0.0001 after Bonferroni adjustment for multiple comparisons, Figure 2a ). NEP was also significantly higher in subjects with a family history of cardiovascular disease (0.18 versus 0.30 nmol l À1 , respectively, Po0.001). Plasma NEP correlated with fasting insulin (r ¼ 0.3, Po0.001), HOMA (r ¼ 0.3, Po0.001), BMI (r ¼ 0.34, Po0.001), tPA (r ¼ 0.44, Po0.001) and PAI-1 (r ¼ 0.41, Po0.001) in all subjects. In a linear regression analysis (excluding subjects with NEP below the assay threshold), significant predictors of plasma NEP concentration were triglyceride, tPA, DBP and PAI-1, which together explained 25% of variance in NEP.
Receiver operating characteristic curve analysis was used to determine a cut-point for NEP in relation to MetS IDF (see Figure 2b , inset); on the basis of this analysis, NEP was Figure 2b) .
NEP mRNA levels are increased during differentiation of human adipocytes
As shown in Figure 3a , human SGBS pre-adipocytes expressed NEP mRNA (CT value B25), and this was increased B25to 30-fold, during adipocyte differentiation. At the protein level, NEP was similarly increased when human SGBS pre-adipocytes differentiated into mature adipocytes (Figure 3b ). To examine the expression levels of SGBS adipocyte-derived NEP, Affymetrix human 133 plus 2 gene chip arrays (Affymetrix UK Ltd) (47 400 transcripts) of differentiating SGBS cells indicated expression of NEP mRNA at levels comparable with that of known adipokines, such as adiponectin, retinol-binding protein 4 and PAI-1 (Figure 3c ) and at least five times higher than the average gene signal.
Neprilysin plasma levels are higher in obese HFD-fed mice Male C57BL/6J mice fed NCD or HFD showed significant differences in weight after 6 weeks and at 14 weeks, total body weight was 34.1±3.0 and 47.6±1.8 g, respectively (Po0.05). At the end of the feeding period, there was an increase in epididymal, mesenteric and perirenal fat by 47.5, Neprilysin and the metabolic syndrome KF Standeven et al 29.5 and 25.9%, respectively, in the HFD-fed mice compared with NCD-fed mice (data not shown). Metabolic characterization and determination of NEP levels were performed on mice after 14 weeks of diet. As described previously, 27 HFD-fed mice exhibited a significant impairment in glucose tolerance compared with NCD-fed mice. Consistently, insulin sensitivity was impaired at this time point (n ¼ 8;
Po0.05) (data not shown). In parallel to the increase in body weight and the impairment in glucose homoeostasis, plasma NEP levels were significantly higher in HFD-fed mice both at 7 and 15 weeks of diet compared with NCD-fed mice (15 weeks: HFD, 1642± 529 pg ml À1 ; NCD, 820±487 pg ml À1 ; Po0.01). Furthermore, the increase in NEP plasma levels comparing 7 and 15 weeks was significant in HFD-fed mice, but not in NCD-fed mice (n ¼ 8; Po0.05) (Figure 4a ). NEP tissue levels at 15 weeks were significantly higher in mesenteric adipose tissue of HFD-fed mice compared with NCD-fed mice (n ¼ 8; Po0.05), but no significant changes in NEP levels in epididymal, perirenal, liver or kidney tissue were observed (Figure 4b ).
NEP knockout does not lead to changes in metabolic characteristics in normal chow and high-fat-fed mice
We investigated the effect of NEP deficiency on glucose and insulin tolerance, and total and epididymal fat pad weight, and found no difference between NEPKO and wild-type littermates on either diet ( Figure 5 ). Both NEPKO and WT HFF mice differed significantly from NCF mice in all parameters (Po0.05) ( Figure 5 ).
Discussion
Substantial interest has been generated in the factors involved in the development of the tight relationship between insulin resistance, type 2 diabetes and cardiovascular disease, and much attention has been focused on the role of the adipocyte in these processes. Clinically, the appearance of obesity seems to drive the development of insulin resistance in many individuals and this is often associated with clustering of cardiometabolic risk factors. NEP fulfils some of the criteria for having a role in cardiometabolic risk: data indicates that it is expressed by the adipocyte and has a role in blood pressure regulation and in animal studies, there are indications that NEP inhibition is associated with enhanced insulin sensitivity. [9] [10] [11] There are also data indicating that NEP cleaves GLP-1, 24 suggesting potential for an influence on insulin secretion in addition to insulin sensitivity, but the relative clinical importance of these effects requires elucidation. In a previous study, we have observed significant correlations between circulating levels of NEP and the presence of the MetS and hypertension, as well as levels of triglyceride. 16 In the present study, we have confirmed that NEP is independently associated with the MetS IDF and its subcomponents, increasing progressively with BMI, HOMA and increasing number of MetS components, and that NEP correlated with haemostatic cardiovascular risk factors, extending our original observations. The clinical association between NEP and cardiovascular risk raises the question as to whether these findings reflect association or causation. In addition to lipid storage, adipose tissue acts as an endocrine organ releasing adipokines and Neprilysin and the metabolic syndrome KF Standeven et al cytokines, including adiponectin, tumour necrosis factor-a and interleukin-6. 25 NEP expression has previously been demonstrated on the surface of isolated pre-adipocytes and adipocytes 8 and we employed SGBS cells, a human preadipocyte cell line with high capacity for adipose differentiation to evaluate adipocyte NEP expression in vitro. 21 We interrogated microarray data from 14-day differentiated SGBS adipocytes and revealed expression levels of NEP higher than most other genes, and of the same order of magnitude as adiponectin and PAI-1, which are established adipokines. We also found a 28-fold increase in NEP mRNA expression and a 13-fold increase in NEP protein expression during a 14-day time course of adipocyte differentiation. These data are in support of a previous study by Moro et al., who found a progressive increase in NEP mRNA and protein levels during human pre-adipocyte differentiation. 26 However, NEP is not required for adipose differentiation in vivo, as we observed that NEPKO mice both under normal and high-fat feeding conditions did not vary substantially in total body or epididymal fat pad weight. The hypothesis that NEP expression in differentiated adipocytes provides a source for circulating NEP is supported by our murine data that demonstrated comparable NEP protein expression in adipose tissue and kidney in NCD-fed mice. We demonstrated that plasma NEP concentration increased as obesity and insulin resistance developed in HFD-fed mice, a change mirrored by increased protein expression of NEP in adipose tissue, in particular in mesenteric fat. In contrast, no significant increase in NEP protein expression was observed in kidney and liver under these circumstances. It would be important to evaluate whether increasing obesity drives adipocyte NEP expression in humans in an analogous manner.
There are two mechanisms by which NEP could contribute to increased insulin resistance. First, it cleaves bradykinin, which has an important role in the modulation of glucose metabolism in peripheral tissues. In adipocytes, bradykinin increases insulin sensitivity by enhancing GLUT4 translocation, IRS-1 phosphorylation, the interaction of IRS-1 association with the p85 regulatory subunit of PI3 kinase and phosphorylation of Thr 308 and Ser 473 of Akt/PKB. 27, 28 The observed increase of bradykinin in the presence of ACE inhibition has been described as a possible mechanism for ACE-inhibitor-induced increased insulin sensitivity. An increase in NEP could lead to an imbalance in bradykinininduced regulation of glucose uptake in the cell, thereby contributing to insulin resistance. Second, studies in cancer cell models have demonstrated that the intracellular domain of NEP directly interacts with phosphatase and tensin homologue tumour suppressor protein. Contact between the negatively charged phosphorylated region in the C terminus of phosphatase and tensin homologue and a cationic alkaline stretch in the N-terminal intracellular tail of NEP targets phosphatase and tensin homologue to the cell membrane and enhances its stability and phosphatase activity, leading to a decrease in insulin signaling via the PI3/Akt axis. 29 However, our studies of a diet-induced model of obesity in mice deficient of NEP did not result in a change in glucose tolerance and insulin sensitivity compared with wild-type littermates fed the same diet, suggesting that the increased NEP observed in the wild-type high-fat feeding model is not a cause of insulin resistance. Increases in plasma NEP could still be responsible for pathophysiological changes observed in insulin resistance. The published literature strongly supports a role for systemic NEP in the regulation of blood pressure: in both human studies and animal models, dual ACE/NEP inhibition was more beneficial in reducing blood pressure than ACE inhibition alone, 30, 31 whereas treating normotensive subjects with a dual ACE/NEP inhibitor resulted in favourable renal hemodynamic effects, including a reduction in blood pressure. 32 These data indicate that NEP has additional or independent effects on blood pressure over and above ACE, supporting our observation of an independent association between NEP and elevated blood pressure in the current work. A mechanism linking increased NEP activity in plasma to hypertension could be provided by increased degradation of vasoactive peptides, such as bradykinin or the natriuretic peptides, leading to endothelial dysfunction, decreased vasorelaxation and elevated blood pressure. In support of this, recent animal studies have shown that candoxatril, a specific NEP inhibitor, improves endothelial dysfunction and reduces intimal hyperplasia as well as PAI-1 production. 33 The in vitro observation that addition of fatty acids or glucose to human microvascular endothelial cells increases NEP activity 34, 35 raises the possibility that metabolic cycling from euglycaemic insulin resistance to type 2 diabetes may provide the hyperglycaemic and dyslipidaemic environment to further enhance the deleterious vascular effects associated with local upregulation of NEP, with detrimental consequences on endothelial function, and further predisposition to cardiovascular disease.
In conclusion, the present study has shown that obesity and the development of insulin resistance are associated with increased plasma and adipose tissue NEP levels and that there is an increase in NEP expression during adipocyte differentiation. The relationship of NEP to dyslipidaemia, and elevated blood pressure independent of insulin resistance supports pleiotropic effects of NEP in relation to cardiovascular risk, which may be partly mediated by the development of endothelial dysfunction.
Limitations of our study
Although we have shown in our murine model of obesity that NEP increases in fat tissue and plasma as a consequence of high-fat feeding, we have no direct evidence that circulating NEP is derived from adipocytes, or that soluble NEP represents NEP activity in tissues, even though our study suggests that this could be a possibility. We have shown that in our cell culture experiments, NEP gene and protein expression increases significantly during cell Neprilysin and the metabolic syndrome KF Standeven et al differentiation, but in preliminary experiments using phorbol ester and calcium ionophore to stimulate shedding of membrane bound NEP, we were unable to detect release of NEP from SBGS cells into culture medium under these experimental conditions (data not shown). Thus, it appears that if adipocytes significantly contribute to plasma levels of soluble NEP, it would be highly likely that release of NEP from the adipocyte involves an extracellular signal, activating the appropriate cell surface sheddase mechanism.
We are currently carrying out further work to explore this possibility. We chose to use SGBS cells to carry out cell culture experiments because they offer an almost unlimited source of pre-adipocytes. SGBS cells are a widely accepted tool for the study of human adipocyte biology, reported by previous publications as comparable with isolated primary human pre-adipocytes. 36 
